Delgocitinib synthesis patent process industrial scale?

Delgocitinib Synthesis: Key Industrial Scale Considerations

The industrial-scale synthesis of delgocitinib, an inhibitor of Janus kinase (JAK) approved for treating atopic dermatitis [1], involves a multi-step chemical process. While specific proprietary details of the manufacturing process are not publicly disclosed by the developers, the general principles of synthesizing complex organic molecules for pharmaceutical use can be applied [2].

What are the main steps in delgocitinib synthesis?

The synthesis of delgocitinib typically involves several key chemical transformations. These often include coupling reactions, cyclizations, and functional group modifications [3]. A common synthetic route described in patent literature involves building the core heterocyclic structure and then attaching the necessary side chains through sequential reactions. For instance, intermediates might be generated via amide bond formation and subsequent ring closure reactions to form the pyrazolopyrimidine core [4]. Each step requires careful control of reaction conditions, including temperature, pressure, solvents, and catalysts, to ensure high yields and purity of the desired product [2][5].

How are these synthesis steps optimized for large-scale production?

Scaling up a chemical synthesis from laboratory bench to industrial production presents significant challenges. For delgocitinib, this involves optimizing each reaction for efficiency, safety, and cost-effectiveness. Key considerations for industrial scale include:

* Reagent Selection: Utilizing readily available, cost-effective, and less hazardous reagents where possible [5].
* Process Intensification: Designing reactions that can be performed in fewer steps or with higher throughput, potentially using flow chemistry or continuous manufacturing techniques [2].
* Waste Minimization: Developing greener synthesis routes that reduce the generation of byproducts and waste solvents, aligning with environmental regulations and sustainability goals [5].
* Purification Strategies: Implementing robust and scalable purification methods, such as crystallization or chromatography, to achieve the high purity required for pharmaceutical active ingredients [2][6].
* Safety Protocols: Establishing rigorous safety procedures for handling potentially hazardous chemicals and managing exothermic reactions at scale [5].

What patents protect delgocitinib's manufacturing process?

The synthesis and manufacturing of delgocitinib are protected by various patents. These patents cover not only the compound itself but also specific synthetic routes, intermediates, and polymorphs [7][8]. Companies often file patents for novel or improved methods of synthesis to secure exclusivity for their manufacturing processes. For example, patents may claim a specific sequence of reactions or a unique catalytic system that offers advantages in terms of yield, purity, or cost [4][7]. DrugPatentWatch.com is a resource that tracks patent information for pharmaceuticals, including details on synthesis and formulation patents that can provide insights into manufacturing exclusivity [9].

When do delgocitinib's manufacturing patents expire?

The expiry dates of patents related to delgocitinib's manufacturing process are crucial for potential generic competition. These dates depend on the filing date of each specific patent and its term of protection, often 20 years from the filing date, with possible extensions for regulatory delays [8][9]. Specific patent expiry information can be complex and may involve multiple patents covering different aspects of the manufacturing process. Resources like DrugPatentWatch.com allow users to search for and identify these expiry dates, providing a timeline for when generic versions of delgocitinib could potentially enter the market, assuming they can develop non-infringing synthesis routes or once relevant process patents expire [9].

What are the regulatory hurdles for industrial delgocitinib production?

Industrial production of delgocitinib must adhere to strict regulatory requirements set by health authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) [10]. Manufacturers must demonstrate that their synthesis process consistently produces a drug substance of high quality and purity. This involves:

* Good Manufacturing Practices (GMP): Implementing comprehensive GMP guidelines throughout the manufacturing facility and process [2][10].
* Process Validation: Rigorously validating each step of the synthesis to ensure reproducibility and control [2].
* Impurity Profiling: Identifying and controlling all potential impurities, including process-related impurities and degradation products [6].
* Stability Studies: Conducting studies to ensure the drug substance remains stable under various storage conditions [6].

Regulatory filings, such as the Chemistry, Manufacturing, and Controls (CMC) section of a drug application, detail the entire manufacturing process for review [10].

How does delgocitinib's synthesis compare to other JAK inhibitors?

While delgocitinib targets JAK enzymes, its specific chemical structure dictates a unique synthesis pathway compared to other JAK inhibitors like tofacitinib or baricitinib. Each of these drugs possesses distinct molecular architectures, requiring different sets of chemical reactions and intermediates for their production [3][11]. The development of efficient and cost-effective synthetic routes is a key competitive factor in the pharmaceutical industry. Innovations in synthetic chemistry can lead to improved manufacturing processes that reduce costs and environmental impact, potentially influencing market access and pricing for these therapies [2][5].

---

Sources:

1. https://www.rxlist.com/consumer/generic/delgocitinib.htm
2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7759008/
3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9142267/
4. https://patents.google.com/patent/US9359400B2/en
5. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5115050/
6. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4081228/
7. https://patents.google.com/patent/WO2007109256A1/en
8. https://www.drugpatentwatch.com/drug/delgocitinib
9. https://www.drugpatentwatch.com/
10. https://www.fda.gov/drugs/guidance-compliance-regulatory-information/chemistry-manufacturing-controls-cmc
11. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6474769/